Radient Pharmaceuticals Corporation fka RXPC

[lakeshore555]

It's good to look at the UNI agreement -- we have nothing else to look at.

The important sections in the legal license document, IMO, are:

1.10 “Royalty(ies”) means the royalty license payments due in accordance with Exhibit B.

Exhibit B shows that "Royalties" mean the $100,000 annual payments and nothing else.

There can be mo misinterpreting this. There are no additional royalties for revenues.

FYI, The SEC filing also has a table of "Intellectual Property" in Exhibit A that shows all the patents:

http://yahoo.brand.edgar-online.com/displayfilinginfo.aspx?FilingID=9359439-6848-61976&type=sect&dcn=0001213900-13-003193

Exhibit A shows that DR-70 is not currently protected by patents outside the USA. Once UNI learns how to manufacture DR-70, what is UNI's motivation to keep paying Radient $100,000 per year? Unless the WIPO patent gets approved, of course... but that is almost five years old.... looks like the WIPO patent application has the same problems as the USA patent.

Not that any of this really matters. Nobody is going to make money selling DR-70, IMO. UNI is going to find out soon enough. The only market for DR-70 appears to be clinical use.